horiz (2)horiz (2)horiz (2)horiz (2)
  • Solutions
    • PepsinCheck
    • Reflux Band
    • Dx-pH System
    • Stretta
    • Secca
  • Clinicians
  • Patients
  • Blog
  • Events
  • Clinical Library
  • Login
✕
Secca Workshop Held in University College London Hospital
February 13, 2012
First Stretta and Secca Cases in India at Endocon 2012
May 4, 2012

As many as 20 million young American women may be silently suffering from a debilitating disorder that few have heard of and even fewer admit to; that disorder is BCD, or Bowel Control Disorder.

Although the prevalence of bowel control disorder and the extent of its impact on quality of life are drastically under-reported, there are several significant facts about it that are known.  Chief among them are that BCD can be a severely debilitating condition, and that it overwhelmingly targets women—particularly women who have had children.  What’s unknown is exactly how many women are affected.  The commonly accepted estimate in population-based studies is that one in 13 people suffers from BCD.  Considering the population as a whole this may be accurate, but looking specifically at the high-risk population for BCD—that is women, and in particular women who have given birth—the numbers may well be four times that of the overall population estimate.

Assuming this estimate is correct, or even close to correct, undiagnosed BCD is an epidemic of greater proportion than undiagnosed Type II diabetes, which is believed to exist in seven million Americans. And though BCD is not life threatening, like diabetes it can have a tremendous effect on quality of life. BCD, in fact, is a common side effect of poorly managed diabetes.

A major factor in the under-reporting of BCD is the silent suffering due to the embarrassment of those affected. Data demonstrate that only one in five younger female patients is willing to initiate a discussion related to incontinence with their primary caregiver. Sufferer silence thus gives way to primary caregivers’ lack of awareness of disorder prevalence, which then prevents patient referral to specialists with knowledge of the latest methods of treatment. This cycle most often ends unresolved, resulting in absurdly low numbers of sufferers getting the counselling and treatment they desperately need.

With regard to caregiver awareness, a common misconception among physicians is that bowel incontinence is a disease of “little old ladies”. Undoubtedly this is because elderly women tend to be the only women who seek treatment. Although it’s a fact that nearly 50 percent of nursing home residents have bowel incontinence, BCD is hardly a disorder of the elderly. A series of studies document that not only does BCD occur widely in women of childbearing age, but that by and large younger sufferers accept a poor quality of life rather than broach this subject with their doctor.

____________________________________________________________________________

“Incidence of Fecal Incontinence After Childbirth”, published in Obstetrics and Gynecology, February 2007 presented the following:  In this study group of women who delivered babies in Oregon in mid-to-late 2002, twenty-nine percent of the 8000+ respondents experienced bowel incontinence after childbirth. Nearly half of these women reported an incontinence event during intercourse.

_____________________________________________________________________________

“Anal Incontinence after Vaginal Delivery: A Five-Year Prospective Cohort Study”, published in American Journal of Obstetrics and Gynecology, December 2004, studied first-time mothers with and without sphincter tears. It was determined that in both groups the incidence and symptoms of BCD at five months, nine months and five years post delivery was high, and worsened over time. Success rates in primary repair of sphincter injuries was frequently disappointing, with incontinence developing in approximately 40 percent of patients.

_____________________________________________________________________________

“Anal Incontinence in Women Presenting for Gynecologic Care: Prevalence, Risk Factors and Impact upon Quality of Life”, published in American Journal of Obstetrics and Gynecology, November 2004 demonstrated that  BCD is prevalent among women presenting for routine GYN visits, that only 11 percent  of  sufferers had sought care for the problem and 83 percent had never been asked BCD questions by their physician.

_____________________________________________________________________________

Given the stigma associated with BCD, it cannot be left to patients to initiate a discussion of the disorder. In every primary care visit by women of childbearing age or older, physicians need to ask the question, “In the last year have you experienced symptoms of bowel control disorder?”  This should be followed by the statement, “It’s much more common than you may think”.

The estimate, in fact, is that some degree of the disorder is experienced by as many as one in three women—or up to 20 million American women younger than 55. Among this number, based on current US divorce statistics, are some 10 million women who may be seeking new mates, but who are in the embarrassing situation of being victims of BCD.

To ensure proper treatment, physicians need to stay current on all treatment options.  As well, hospitals need to market new treatments to alter the perception of most BCD sufferers that no viable solution to their problem exists.

For the few patients who have actively sought help for their disorder, depending on the severity of their symptoms the treatment pathway usually has begun conservatively.  Initial treatment has included dietary changes, constipating drugs, exercises and biofeedback. If these measures failed, with no other option, the next step has been a significant leap to invasive surgery, such as sphincter repair, an artificial sphincter or a colostomy—expensive, marginally effective and/or disfiguring.  Many patients appear not to have chosen that option.

Assuming the estimate of 20 million young, female BCD sufferers is accurate, the following study validates the enormous gap between the number of sufferers, and the number of surgical treatments for the condition.

The Study, “National Trends and Costs of Surgical Treatment for Female Fecal Incontinence”, presented at The Society of GYN Surgeons in April, 2007, showed that during the five-year study period (1998 to 2003) the number of annual surgical procedures for BCD remained flat at approximately 3,500, while costs continued to escalate.

In summary, bowel control disorder will never be proper dinner-table conversation, or perhaps ever be an appropriate topic for television commercials, but it needs to come out of the bathroom and into the offices of primary care physicians. Only then, when the disorder is routinely discussed with female patients of childbearing age or older, can the stigma lessen and the epidemic proportions of this now-little-known disorder be diminished.

Author: William Rutan 

Published online January 2010, www.massdevice.com
http://www.massdevice.com/whitepapers/epidemic-incidence-little-known-disorder”>http://www.massdevice.com/whitepapers/epidemic-incidence-little-known-disorder

REFERENCES:
Incidence of Fecal Incontinence After Childbirth. Jeanne-Marie Guise, MD, MPH, Cynthia Morris, PhD, MPH, Patricia Osterweil, Hong Li, MD, MSPH, Deborah Rosenberg, and Merwyn Greenlick, PhD. Obstetrics and Gynecology, February 2007.

Anal Incontinence After Vaginal Delivery: A Five-year Prospective Cohort Study. John Pollack, MD, Johan Nordenstam, MD, Sophia Brismar, MD, Annika Lopez, MD, PhD, Daniel Altman, MD, and Jan Zetterstrom, MD, PhD. American Journal of Obstetrics and Gynecology, December 2004.

Anal Incontinence in women presenting for gynecologic care: Prevalence, risk factors, and impact upon QOL. Muriel K. Boreham, MD, Holly E. Richter, PhD, MD, Kimberly S. Kenton, MD, Charles W. Nager, MD, W. Thomas Gregory, MD, Michael P. Aronson, MD, Val Y. Vogt, MD, Don D. McIntire, PhD, Joseph I. Schaffer, MD. American Journal of Obstetrics and Gynecology, November 2004.

National trends and costs of surgical treatment for female fecal incontinence. Vivian W. Sung, MD, MPH; Michelle L. Rogers, PhD; Deborah L. Myers, MD; Homayoon M Akbari, MD, PhD; Melissa A. Clark, PhD. American Journal of Obstetrics and Gynecology, December 2007.

 

 

 

 

 

 

 

 

Share

Related posts

March 3, 2022

Study finds significant correlation between LPR and Allergic Rhinitis


Read more
January 18, 2021

16 Million New Patients Covered for Stretta Therapy


Read more
November 19, 2020

Minimally Invasive Stretta Antireflux Procedure Accessible to Millions more Patients


Read more
Epidemic Incidence of a Little Known Disorder
CONTACT

US: +800.352.1512
Int'l: +1 858.673.3700
Fax: 858.673.3783 contact@restech.com

Contact

Distributor Login
Clinician Login
Representative Login

How we Help

Solutions
PepsinCheck
Reflux Band
Restech
Stretta
Secca

About Us

Company
Contact Us
Job Opportunities
International Distributors
Compliance
Privacy Policy
Terms of Use

Follow Us

Respiratory Technology Corporation 11011 Brooklet Dr, Ste 300 Houston TX 77099 | © 2019 Restech. All Rights Reserved.
    FIND A DOCTOR
      Bree Gorman, VP Marketing

      Bree has been an integral part of Restech from the very beginning. She holds a Masters in Public Health from George Washington University, a BFA from The University of Kansas in Visual Communications, and is a National Board Certified Health & Wellness Coach. Her command of marketing, public health/health delivery systems, and human health behavior change gives her a unique perspective in developing effective marketing strategies for the company.  

      Physicians: Fill out the form below to complete your request to be added to the “Find-A-Doctor” map on restech.com

       


      Thomas Ball, PhD, VP Clinical Affairs

      Thomas previously worked as a polysomnographic technologist in the Virginia Mason system, before  moving into sales with Restech in 2007. After spending 9 years working with distributors across Europe, he was moved into an organizational role at the head office in Houston. In this capacity he works closely with sales and marketing to provide clinical support, manages clinical studies, and provides clinical perspectives on business development. In his spare time Thomas plays rugby for Houston Athletic Rugby Club.

      Jeff Klindworth, VP Business Development

      Jeff has over 30 years of experience in the medical device industry and previously worked in sales at companies such as Encision Inc., Interventional Therapies, LLC, Boston Scientific, and United States Surgical Corporation. He has been working as the VP of Sales for Mederi Therapeutics since 2009 and now brings his extensive expertise to Restech.  Jeff was part of the team that bridged the Mederi asset sale to Restech.  His clinical knowledge of the Stretta and Secca technologies is invaluable.  Jeff has three decades of physician relations experience that he brings to Restech as part of the leadership team.

      Ray Bengermino, VP Sales

      Ray joined Restech in May 2018 as the Vice President for Sales. He has been in the medical device, and specifically in the GERD space for more than 18 years. Starting in sales at Sandhill Scientific pH diagnostics, he moved on to Curon Medical when Stretta and Secca were first introduced to the market. He then worked for Given Imaging when Curon closed operations.  When Stretta was relaunced he joined Mederi as VP of Sales.  Ray was instrumental in keeping Stretta alive and the customer based informed when Mederi ceased operation and assets were purchased by Restech.  He is part of the leadership team directing all product sales for Restech. Ray graduated from Old Dominion University in Norfolk with a BS in Marketing and Business Administration.

      Mark Clark, CPA, CFO

      Mark is a seasoned professional and Certified Public Accountant in Texas who brings a unique blend of creative vision and financial expertise to any leadership team. He worked as a Senior Executive for 15 years on a leadership team which grew a private equity backed cash logistics company performing at negative EBITDA on $100 million revenue into an international industry leader with superior profitability on revenue exceeding $1.5 billion. In addition, he spent 10 years as a Senior Manager at Price Waterhouse delivering results-oriented merger & acquisition, audit and strategic consulting services to middle market clientele including over 40 manufacturing, distribution, service, nonprofit and technology clients. Mark currently serves as a Chief Financial Officer and consulting CFO (seven years) providing in-house and outsourced CFO and transactional services to the middle market.

      Larry Suarez

      Larry is the CTO for Restech and holds a B.S. in Computer Science. He is a software architect specializing in remote patient monitoring, medical sensors, and clinical trial software. Larry holds a patent on massively distributed computing and has worked for a number of major software startup companies including Sybase, Oracle, and Teradata.  Larry was also the co-founder of a startup to deliver advanced clinical pathways to patients using mobile devices and medical sensors. Larry is truly a pioneer and now a veteran in the deployment.

      Jeff Schipper

      Jeff has a breadth of experience with over 25 years in engineering and executive positions within major fortune 100 healthcare companies. He also has proven success in startup medical technology companies. Jeff provides leadership in securing and managing Restech’s patent portfolio. He also built Restech’s compliance platform that established regulatory acceptance in 25+ countries worldwide. Jeff’s scientific support and in-depth understanding of the device industry set the foundation for current and future commercial innovations at Restech.

      Leo Roucher

      With nearly 30 years of working with physician thought leaders developing novel and emerging technologies, Leo has played a key role in the development and evolution of balloon angioplasty and stent technologies that revolutionized the therapy of cardiac disease. His experience was instrumental in the development of the patented platform technology which drives the Restech sensor. Leo provides a vision and passion for effecting change in the diagnosis and management of atypical reflux.

      Deb Krahel

      With over 20 years of executive experience in both the private and public sector, Debra brings a broad understanding of healthcare delivery system. With experience managing products aimed at wide scale disease and population management for 20 million subscribers, Debra has extensive experience in effectively and efficiently developing models of delivery that address specific health issues. Debra has also been involved in the legislative process and served as the elected President of the Independent Physician Association of California. Debra is dedicated to bringing tools to the healthcare market that improve and support the clinical process.